| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
The current standard therapy for chronic hepatitis C is based on pegylated-interferon (PEG-IFN)/ribavirin (RBV). In 2011, HCV protease inhibitor entered the clinical stage. The new treatment with protease inhibitor is also based on a combination of PEG-IFN/RBV. In 2009, SNPs upstream from the IL28B gene has been reported as strong predictive host factors of the effect of PEG-IFN/RBV. However, the precise mechanism underlying this influence is unclear. Therefore, we examined the IL28B genotypes for human hepatocyte cell lines in order to develop a cell culture model. HCV permissive Li23 and HuH-7 cells are exhibited IFN-sensitive and -resistant IL28B SNPs, respectively. The sensitivities to IFN-α are not significantly different in HCV harboring Li23 and HuH-7 cells. However, IFN-λ exhibited 100 times higher inhibitory effect on HCV RNA replication in Li23 cells than in HuH-7 cells. These HCV cell culture systems are useful tools for the study of IL28B SNPs and HCV.
|
